Rivastigmine is an inhibitor of acetylcholinesterase (AChE) and butylcholinesterase (BChE) that is used clinically to treat dementia. Rivastigmine exhibits anti-cholinergic, anti-inflammatory, cognition enhancing and neuroprotective activities. In vivo, rivastigmine improves memory impairment in a CaMKII-dependent manner. Rivastigmine also decreases production of IL-1β in vivo. In vitro, this compound displays benefit against Alzheimer’s disease, increasing secretion of amyloid-β (Aβ) precursor protein (APP) and decreasing secretion of Aβ through modulation of α-secretase signaling.